Angelina Jolie inadvertently highlights key question of gene patents

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The following is an excerpt.

Angelina Jolie’s recent double mastectomy was obviously a very radical decision. It is unusual for a healthy person to opt for pre-emptive surgery to avert the probability, however high it may be, of getting cancer. The tests Jolie relied on are also at the heart of a legal battle, which could affect US biotech patenting norms. Since the US is the global R&D leader, and other nations tend to fall in line with US practice, the outcome will have a far-reaching impact on research into stem cells, vaccines, antibiotics, insulin, enzymes and so on.

Read the full story here: Can genes be patented?

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend